Dexcom G7 Continuous Glucose Monitoring System Gets Regulatory Nod From Health Canada
Portfolio Pulse from Nabaparna Bhattacharya
DexCom, Inc.'s (NASDAQ:DXCM) Dexcom G7 Continuous Glucose Monitoring System has been approved by Health Canada. The device can warn of high or low glucose levels and help avoid hypoglycemic events. The approval gives Canadians access to a technology that reduces hospitalizations and emergency room visits due to hypoglycemia by up to 42%. The product is expected to be launched in Canada by the end of 2023.
July 05, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DexCom's Dexcom G7 has received regulatory approval from Health Canada. This could potentially increase the company's market share in Canada and lead to increased revenues once the product is launched.
The approval of Dexcom G7 by Health Canada is a significant milestone for DexCom. This could potentially increase the company's market share in Canada, as it provides a new tool for diabetes management. The product's ability to reduce hospitalizations and emergency room visits due to hypoglycemia by up to 42% could make it a preferred choice among patients, leading to increased sales and revenues once the product is launched.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100